Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
February 12, 2020
Redoxis

NeutroCure kick-off meeting

NeutroCure kick-off meeting

-
Redoxis
-
February 12, 2020

Last week, we successfully kicked off the Horizon 2020 funded FETOPEN program NeutroCure (agreement No 861878). The consortium, with partners from Friedrich-Alexander-Universitaet Erlangen Nuernberg and Universitatsklinikum Erlangen (Germany), University of Surrey (UK), Lvivskyi Nationalnyi Medychinyi Universytet Imeni Danyla Halytskoho (Ukraine), Centro Nacional de Investigiciones Cardiovasculares Carlos III (F.S.P) (Spain) and Institute Gustave Roussy (France) meet in Erlangen for a day of discussions on neutrofils and oxidation in regulation of the immune system. Redoxis look forward to the next five years of collaboration and the research that will be the result of this. We aim to identify candidate ROS amplifier drugs and prodrugs to treat pathogenic conditions arising due to insufficient production of reactive oxygen species (ROS), including autoimmune disease, cancer and bone marrow ablation. We will advance these drugs from lab bench to pre-clinical validation studies obtaining new drugs with strong therapeutic value.

Last updated:
February 12, 2020

Redoxis

Redoxis performs tailor-made preclinical studies combining dedication, experience and agility to provide reliable results to your project.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail

Last week, we successfully kicked off the Horizon 2020 funded FETOPEN program NeutroCure (agreement No 861878). The consortium, with partners from Friedrich-Alexander-Universitaet Erlangen Nuernberg and Universitatsklinikum Erlangen (Germany), University of Surrey (UK), Lvivskyi Nationalnyi Medychinyi Universytet Imeni Danyla Halytskoho (Ukraine), Centro Nacional de Investigiciones Cardiovasculares Carlos III (F.S.P) (Spain) and Institute Gustave Roussy (France) meet in Erlangen for a day of discussions on neutrofils and oxidation in regulation of the immune system. Redoxis look forward to the next five years of collaboration and the research that will be the result of this. We aim to identify candidate ROS amplifier drugs and prodrugs to treat pathogenic conditions arising due to insufficient production of reactive oxygen species (ROS), including autoimmune disease, cancer and bone marrow ablation. We will advance these drugs from lab bench to pre-clinical validation studies obtaining new drugs with strong therapeutic value.

Last updated:
February 12, 2020

Redoxis

Redoxis performs tailor-made preclinical studies combining dedication, experience and agility to provide reliable results to your project.

Click here to read more about us!
Get in touch with us!
Visit us
Send us mail